NASDAQ: ATXIAvenue Therapeutics Inc Stock
$1.36+0.04 (+3.03%)
Updated Feb 13, 2025
ATXI Price
$1.36
Fair Value Price
N/A
Market Cap
$2.60M
52 Week Low
$1.22
52 Week High
$15.00
P/E
0.07x
P/B
1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.37
Operating Cash Flow
-$11M
Beta
0.57
Next Earnings
Mar 17, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ATXI Overview
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATXI's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
F
Momentum
C
Sentiment
D
Safety
F
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATXI
Ranked#555 of 560
Ranked#555 of 560
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.86 | A | |
| $136.82 | A | |
| $5.58 | A |
Be the first to know about important ATXI news, forecast changes, insider trades & much more!
ATXI News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATXI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATXI is good value based on its earnings relative to its share price (0.07x), compared to the US market average (38.39x)
P/E vs Market Valuation
ATXI is good value based on its earnings relative to its share price (0.07x), compared to the US Biotechnology industry average (-174.82x)
P/E vs Industry Valuation
ATXI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ATXI due diligence checks available for Premium users.
Valuation
ATXI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.07x
Industry
-174.82x
Market
38.39x
ATXI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ATXI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ATXI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1x
Industry
4.78x
ATXI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATXI's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
ATXI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.6M
Liabilities
$973.0k
Debt to equity
0.37
ATXI's short-term assets ($2.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATXI's short-term assets ($2.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATXI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ATXI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
$0.0
Financing
$567.0k
ATXI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATXI vs Biotech Stocks
Avenue Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.